ClinicalTrials.gg
Not yet recruitingNCT06636994PRE-SIGHTUpdated Oct 1, 2026

Anatomical and Functional Predictions of Blindsight Capabilities in Patients With Lateral Hemianopsia

An observational study in Homonymous Hemianopia, Stroke and Cortical Blindness, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational

Updated Oct 1, 2026Now Not yet recruitingStart date moved+3 moreGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Homonymous lateral hemianopia (HLH) is characterized by loss of vision in half the visual field, and is the most common neurovisual disorder following stroke.

Numerous behavioral and neuroanatomical studies have focused on the phenomenon of blindsight, corresponding to patients' unconscious residual visual capacities in the blind hemifield. Cohort studies of patients have highlighted different types of blindsight, and a low occurrence of the phenomenon initially described: (1) type 1 blindsight (≈12%), unconscious visual abilities; (2) type 2 blindsight, visual abilities associated with sensations in the blind field (≈18%); (3) blindsense, sensations in the blind field without visual abilities (≈30%); and (4) no blindsight (≈40%). The heterogeneity of these blindsight abilities in the HLH population is closely related to patients' neuroanatomical and functional profiles.

In particular, resting-state functional imaging (r-fMRI) and default mode network analysis have highlighted a significant correlation between the degree of inter-hemispheric connection (between the healthy and injured hemispheres) and the rate of spontaneous visual field recovery. To our knowledge, this degree of functional connectivity has not yet been studied in relation to blindsight abilities. However, this functional MRI measurement tool represents a potential predictive factor for patients' residual performance in their blindsight field, in order to assess the level of visuo-cognitive impairment and, ultimately, to adapt care.

02

Conditions studied

  • Homonymous Hemianopia
  • Stroke
  • Cortical Blindness
  • Hemianopia
03

In context

Hemianopsia

63 studies on the registry are indexed under Hemianopsia; 24 are open to participants now.

Browse Hemianopsia studies →

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients over 18 years of age with homonymous lateral hemianopia undergoing cerebral MRI for follow-up and rehabilitation following stroke

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18 and over
  • with homonymous visual field amputation sequelae of a retrochiasmatic lesion of vascular origin (stroke), including the occipital region (primary visual cortex, optic radiations, associated occipital areas)
  • Requires follow-up brain MRI as part of treatment
  • Able to perform experimental tasks on computer
  • Express consent to participate in the study
  • Member or beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Severe neuropsychological disorders (language, memory, attention, vigilance, reasoning)
  • Severe ophthalmological disorders or visual acuity below 3/10 prior to stroke
  • Progressive ophthalmological disorders (cataract or glaucoma) likely to bias measurements
  • Major psychiatric or behavioral disorders making care impossible
  • Patient benefiting from a legal protection measure
  • Pregnant or breast-feeding women (declarative information)
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Description of resting-state functional MRI measurement of the degree of Resting State Functional Connectivity (RSFC) between left and right hemisphere regions.

    Comparison of the degree of inter-hemispheric Resting State Functional Connectivity between the four patient groups: absence of blindsight, type I blindsight, type II blindsight and blindsense.

    Time frame: DAY 0

Secondary outcomes

  1. Correlation between inter-hemispheric functional connectivity and blindsight performance

    Resting-state functional MRI measurement of the degree of RSFC between left and right hemisphere regions of interest. Blindsight performance assessed by measuring the sensitivity of discrimination of spatial orientation (horizontal/vertical) of lines presented in the patient's blind field (blindsight).

    Time frame: DAY 0

  2. Density and intensity of visual and attentional default networks in each type of blindsight

    Calculation (Graph Theory) of neural network matrices, weighted and created on the basis of correlations of activations in different brain regions during resting-state functional MRI measurement .

    Time frame: DAY 0

  3. Blindsight performance according to the laterality of the lesion (left or right hemisphere)

    Blindsight performance assessed by measuring the sensitivity of discrimination of spatial orientation (horizontal/vertical) of lines presented in the patient's blind field (blindsight)

    Time frame: DAY 0

  4. Correlation between the level of inter-hemispheric functional connectivity and blindsight performance

    Resting-state functional MRI measurement of the degree of Resting State Functional Connectivity (RSFC) between left and right hemisphere regions of interest, blindsight performance assessed by measuring the sensitivity of spatial orientation discrimination (horizontal/vertical) of lines presented in the blindsight field.

    Time frame: DAY 0

  5. Correlation between visual default network density and intensity and blindsight performance

    Computation (Graph Theory) of neural network matrices, weighted and created on the basis of correlations of activations of different brain regions during Resting-state functional MRI measurement. Blindsight performance assessed by measuring the sensitivity of discrimination of spatial orientation (horizontal/vertical) of lines presented in the patient's blind field (blindsight).

    Time frame: DAY 0

  6. Correlation between lesion volume and blindsight performance

    Blindsight performance assessed by measuring the sensitivity of spatial orientation discrimination (horizontal/vertical) of lines presented in the patient's blind field (blindsight).

    Time frame: DAY 0

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Not yet recruiting
changed Oct 1, 2026
Start date
Nov 21, 2024→Oct 2026
Oct 1, 2026
Primary completion
Dec 2029→Oct 2029
Oct 1, 2026
Study completion
Dec 2029→Oct 2029
Oct 1, 2026
Contact
Study contact now listed: added a•••@for.paris · •••6454; added s•••@for.paris · •••6277. See the current contact
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hopital Fondation Adolphe de Rothschild · Paris, FranceContact added c•••@for.paris
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Active, not recruiting→Not yet recruiting
    Start date Nov 21, 2024→Oct 2026
    Primary completion Dec 2029→Oct 2029
    Study completion Dec 2029→Oct 2029
    Contact Study contact now listed: added a•••@for.paris · •••6454; added s•••@for.paris · •••6277. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hopital Fondation Adolphe de Rothschild · Paris, FranceContact added c•••@for.paris
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06636994
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Amelie Yavchitz, Dr
Contact
ayavchitz@for.paris
0148036454
Sadia MEDAOURI
Contact
smedaouri@for.paris
0148036277
Clémentine GARRIC
principal investigator · Integrative Neuroscience and Cognition Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion